SBRASabra Health Care REIT, Inc.

$18.97+6.1% 1Y

Is the price fair?

Watch

At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 to watch, 2 without data
Vs its own P/E rangedearer than 90% of its own historyderived

Expensive vs its own history: P/E 73.0 vs a 16.8 median over 31 quarters (+334% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 8% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What SBRA's price assumes

Sabra Health Care REIT, Inc. trades at 73.0× earnings against 38.1× for the median REIT - Healthcare Facilities name, more expensive than its own group.

73.0

Trailing P/E · REIT - Healthcare Facilities median 38.1 · 1.91× the median: the market pays up for this one

Price / sales
5.67

Price / sales · as of 2026-Q2

Price / book
1.77

Price / book · as of 2026-Q2

EV / sales
8.45

EV / sales

Details›
Price / bookas of 2026-Q2
1.77
EV / salesas of 2026-Q2
8.45
Real Estate median P/E130 names
25.0
REIT - Healthcare Facilities median P/E11 names
38.1
Market capitalisation
$4.87B
SBRA has re-rated away from its own history, so multiplying the old multiple by today's earnings prices a full reversal, not the business
MethodPer share
What its own history would implynot meaningful, 73.0× today against a 16.8× median
52-week range$16.47 – $22.40
Today$18.97

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.